Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

159 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Prostate cancer vaccines: the long road to clinical application.
Baxevanis CN, Papamichail M, Perez SA. Baxevanis CN, et al. Cancer Immunol Immunother. 2015 Apr;64(4):401-8. doi: 10.1007/s00262-015-1667-7. Epub 2015 Feb 19. Cancer Immunol Immunother. 2015. PMID: 25690791 Review.
Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.
Papanastasiou M, Baxevanis CN, Papamichail M. Papanastasiou M, et al. Among authors: baxevanis cn. Cancer Immunol Immunother. 1992;35(2):145-50. doi: 10.1007/BF01741862. Cancer Immunol Immunother. 1992. PMID: 1596938
Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M. Baxevanis CN, et al. Cancer Immunol Immunother. 1995 Jun;40(6):410-8. doi: 10.1007/BF01525392. Cancer Immunol Immunother. 1995. PMID: 7543022
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Baxevanis CN, et al. Cancer. 1994 Aug 15;74(4):1275-82. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q. Cancer. 1994. PMID: 7914469
Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.
Baxevanis CN, Dedoussis GV, Gritzapis AD, Stathopoulos GP, Papamichail M. Baxevanis CN, et al. Br J Cancer. 1994 Oct;70(4):625-30. doi: 10.1038/bjc.1994.361. Br J Cancer. 1994. PMID: 7917907 Free PMC article.
Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy.
Baxevanis CN, Papamichail M. Baxevanis CN, et al. Crit Rev Oncol Hematol. 1994 Jun;16(3):157-79. doi: 10.1016/1040-8428(94)90069-8. Crit Rev Oncol Hematol. 1994. PMID: 8074801 Review. No abstract available.
Induction of lymphokine-activated killer activity in mice by prothymosin alpha.
Baxevanis CN, Gritzapis AD, Dedoussis GV, Papadopoulos NG, Tsolas O, Papamichail M. Baxevanis CN, et al. Cancer Immunol Immunother. 1994 Apr;38(4):281-6. doi: 10.1007/BF01533521. Cancer Immunol Immunother. 1994. PMID: 8168124
Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I, Papamichail M. Baxevanis CN, et al. Cancer. 1993 Jul 15;72(2):491-501. doi: 10.1002/1097-0142(19930715)72:2<491::aid-cncr2820720227>3.0.co;2-1. Cancer. 1993. PMID: 8319179
Prothymosin alpha restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer.
Baxevanis CN, Reclos GJ, Papamichail M. Baxevanis CN, et al. Int J Cancer. 1993 Jan 21;53(2):264-8. doi: 10.1002/ijc.2910530216. Int J Cancer. 1993. PMID: 8425763
Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Beroukas C, Stathopoulos GP, Papamichail M. Baxevanis CN, et al. Cancer. 1995 Oct 1;76(7):1253-60. doi: 10.1002/1097-0142(19951001)76:7<1253::aid-cncr2820760724>3.0.co;2-f. Cancer. 1995. PMID: 8630906
159 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback